TENORMIN Solution for injection Ref.[6738] Active ingredients: Atenolol

Source: Medicines & Healthcare Products Regulatory Agency (GB)  Revision Year: 2017  Publisher: AstraZeneca UK Limited, 600 Capability Green, Luton, LU1 3LU, UK

Product name and form

Tenormin Injection 0.5 mg/ml.

Pharmaceutical Form

Solution for injection or infusion.

Type I clear glass ampoules containing a clear, colourless, sterile solution.

Qualitative and quantitative composition

Atenolol 0.5 mg/ml (5 mg in 10 ml).

For the full list of excipients, see section 6.1.

Active Ingredient Description
Atenolol

Atenolol is a beta-blocker which is beta1-selective, (i.e. acts preferentially on beta1-adrenergic receptors in the heart). Atenolol is without intrinsic sympathomimetic and membrane-stabilising activities and as with other beta-blockers, has negative inotropic effects.
List of Excipients

Citric acid
Sodium chloride
Sodium hydroxide
Water for Injection

Pack sizes and marketing

Glass ampoules.

10 ml ampoules are packed in boxes of 10.

Marketing authorization holder

AstraZeneca UK Limited, 600 Capability Green, Luton, LU1 3LU, UK

Marketing authorization dates and numbers

17901/0050

Date of first authorisation: 1st June 2000

Date of latest renewal: 18th February 2004

Drugs

Drug Countries
TENORMIN Austria, Australia, Canada, Cyprus, Germany, Ecuador, Spain, Hong Kong, Italy, Japan, Malta, Mexico, Nigeria, Singapore, United Kingdom, United States, South Africa
 
Next: Usage >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈